Compugen Ltd
CGEN1.460USD
-0.020-1.35%
終値 08/04, 16:00（ET）15分遅れの株価
130.73M時価総額
損失額直近12ヶ月PER
詳細情報 Compugen Ltd 企業名
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
企業情報
企業コードCGEN
会社名Compugen Ltd
上場日Aug 01, 2000
最高経営責任者「CEO」Mr. Eran Ophir
従業員数74
証券種類Ordinary Share
決算期末Aug 01
本社所在地Azrieli Center
都市HOLON
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号5885849
電話番号97237658585
ウェブサイトhttps://cgen.com/
企業コードCGEN
上場日Aug 01, 2000
最高経営責任者「CEO」Mr. Eran Ophir
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
56.12K
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
--
--
Mr. Eran Ophir
Mr. Eran Ophir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
--
--
Ms. Yvonne Naughton, Ph.D.
Ms. Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Head of Investor Relations and Corporate Communications
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
56.12K
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
データなし
地域別USD
会社名
収益
比率
United States
22.86M
82.06%
Europe
5.00M
17.94%
事業別
地域別
データなし
株主
更新時刻: Wed, Jul 2
更新時刻: Wed, Jul 2
株主統計
種類
株主統計
株主統計
比率
SilverArc Capital Management, LLC
3.23%
Bristol Myers Squibb
2.06%
Renaissance Technologies LLC
1.56%
ARK Investment Management LLC
1.20%
Macquarie Investment Management
1.14%
Other
90.82%
株主統計
株主統計
比率
SilverArc Capital Management, LLC
3.23%
Bristol Myers Squibb
2.06%
Renaissance Technologies LLC
1.56%
ARK Investment Management LLC
1.20%
Macquarie Investment Management
1.14%
Other
90.82%
種類
株主統計
比率
Hedge Fund
7.43%
Investment Advisor
6.81%
Corporation
2.06%
Investment Advisor/Hedge Fund
1.84%
Research Firm
1.05%
Individual Investor
0.06%
Family Office
0.02%
Bank and Trust
0.02%
Other
80.72%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
125
18.24M
20.37%
-2.23M
2025Q1
136
18.21M
20.34%
-1.52M
2024Q4
142
15.38M
17.17%
-4.74M
2024Q3
156
17.98M
20.08%
-1.17M
2024Q2
166
18.25M
20.39%
-8.45M
2024Q1
200
18.75M
20.95%
-8.33M
2023Q4
207
11.97M
13.42%
-16.97M
2023Q3
224
13.03M
14.74%
-15.31M
2023Q2
233
16.58M
19.07%
-11.59M
2023Q1
243
16.04M
18.70%
-15.59M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
SilverArc Capital Management, LLC
2.90M
3.23%
+1.27M
+78.25%
Mar 31, 2025
Bristol Myers Squibb
1.84M
2.06%
-2.92M
-61.32%
Dec 31, 2024
Renaissance Technologies LLC
1.40M
1.56%
+118.07K
+9.24%
Mar 31, 2025
ARK Investment Management LLC
889.67K
0.99%
+889.67K
--
Mar 31, 2025
Macquarie Investment Management
1.02M
1.14%
--
--
Mar 31, 2025
Taylor Frigon Capital Management LLC
1.05M
1.17%
-43.75K
-4.00%
Mar 31, 2025
Rock Springs Capital Management LP
989.99K
1.11%
--
--
Mar 31, 2025
Northern Trust Global Investments Limited
881.24K
0.98%
-60.59K
-6.43%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
802.50K
0.9%
+23.87K
+3.07%
Mar 31, 2025
Morgan Stanley & Co. LLC
583.91K
0.65%
+543.04K
+1328.64%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
ARK Israel Innovative Technology ETF
1.64%
SPDR S&P International Small Cap ETF
0.01%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ARK Israel Innovative Technology ETF
比率1.64%
SPDR S&P International Small Cap ETF
比率0.01%
Invesco NASDAQ Future Gen 200 ETF
比率0%
SPDR Portfolio Developed World ex-US ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
